Skip to main content
Full access
Government News
Published Online: 1 January 2010

Prescribing Buprenorphine May Trigger Random Federal Audit

Abstract

APA is providing information about what to expect in these audits and urges members who encounter problems to contact the Association.
Physicians who administer, dispense, or prescribe Schedule III substances, including buprenorphine, may be required to submit to random audits as a part of routine surveillance by the Drug Enforcement Agency.
The Drug Enforcement Administration (DEA) has recently sent letters to psychiatrists and other physicians who are registered with the DEA stating that it will be conducting on-site, unannounced inspections under the authority of the Controlled Substances Act (CSA).
The inspections are intended to ensure compliance with recordkeeping, security, and other requirements for administering, dispensing, or prescribing controlled substances under the CSA, according to the government agency.
Jennifer Tassler, J.D., deputy director for regulatory affairs in APA's Department of Government Relations (DGR), said that technically inspections can be conducted for any scheduled narcotic, but that the DEA initiative is focused on buprenorphine.
Tassler told Psychiatric News that DGR has been in contact with the agency and that the DEA has said the inspections are routine and not intended to intimidate or harass physicians or their patients.
DGR provided the following information about what to expect and how to alert APA if there is a problem:
•. 
The inspector should present his or her DEA credentials and a “Notice of Inspection” to explain the process of the audit and the physician's rights. Physicians have the right to refuse to consent to the inspection and insist that the DEA obtain an administrative warrant. Members who believe they require legal advice should contact a local attorney.
•. 
DEA agents will likely verify physician credentials including DEA registrations and state licensure and will ask to see three months of records. They will verify the number of patients being treated to ensure that it is in line with the limits outlined in the Drug Abuse Treatment Act of 2000.
•. 
In the case of physicians who are dispensing or administering buprenorphine, DEA agents will likely take an inventory of the product on hand and reconcile that with the records of what was dispensed or administered. The investigator will also be checking to see that the drugs are properly secured within the facility.
•. 
If the DEA investigator finds that there are administrative violations, he or she can issue a “Letter of Admonition” outlining the problems found in the audit. The physician then has 30 days to respond to the DEA with information about how the problem was corrected.
Members who receive an on-site audit and experience any problems should contact APA staff Jennifer Tassler at (703) 907-7842 or Beatrice Eld at (703) 907-8598.

Information & Authors

Information

Published In

History

Published online: 1 January 2010
Published in print: January 1, 2010

Authors

Details

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share